Sumit Garg, M.D. Presented Thirty-Six Months Grail Study Visual Outcomes at the American Society of Cataract and Refractive Surgery Conference

San Diego, Calif., May 6, 2023 – Sumit Garg, M.D., Vice Chair of Clinical Ophthalmology & Medical Director at the Gavin Herbert Eye Institute, University of California, Irvine presented the long-term (36 months) visual outcomes during scientific sessions on Presbyopia Correcting IOLs. Providing both quantity (range) and quality of vision is what sets the Juvene® IOL apart from other presbyopia correcting IOLs.  Key highlights of the data include good outcomes across the full visual range (distance, intermediate and near) are maintained for three years postoperatively.  In addition, accommodative amplitude was maintained during the same period.  Mesopic (low light) contrast sensitivity

LensGen® Closes $5.9 Million Financing

Irvine, Calif., March 2, 2023 – LensGen, Inc., a clinical stage ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, announces the closing of a $5.9 million Bridge Financing.  The financing was led by the corporate venture investment arm of HOYA Group.

LensGen® Receives IDE Approval from the U.S. FDA to Begin Clinical Study of the Juvene® Presbyopia-Correcting Intraocular Lens

IRVINE, Calif., Nov. 29, 2021 /PRNewswire/ — LensGen, Inc., a privately held ophthalmic medical device company, announced today that it has received approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal study of the company’s Juvene intraocular lens (IOL) for patients with cataracts. The LensGen Juvene IOL is designed to permanently restore clear and continuous vision at all distances including near and intermediate. The lens is modular and has a fluid optic component that changes shape to adjust focus on demand for today’s active lifestyles, from viewing mobile devices and computer screens

OIS Podcast – Ram Rao, CEO LensGen – Never Taking No For An Answer

LensGen CEO, Ramgopal Rao Featured in OIS Podcast. “Ram tells his story from the early beginning while collaborating with the late, great Roger Steinert, MD and realizing that they had to go back to the drawing board to reinvent the technology. Rather than throw in the towel after hearing no repetitively from investors, Ram persevered at all costs, subsequently raised $42M to date and emerged with a breakthrough technology to treat cataracts and presbyopia. Listen in for pearls of entrepreneurial wisdom and understand why Ram never took no for an answer.”

LensGen® Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directors

Irvine, Calif., August 20, 2020 – LensGen, Inc., an ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, announces the initial Closing of a $10 million of the $20 million Bridge Financing. The company is also pleased to announce the election of James (Jim) Mazzo to its Board of Directors. The financing was led by the corporate venture investment arm of HOYA Group and is part of a larger Series B Financing planned in early 2021 that will fund the company through approval of Juvene IOL pivotal FDA study. “We


Prof. Dr. Thomas Kohnen to Share Interim “Grail” Study Results at ESCRS in Paris IRVINE, Calif., September 10, 2019 — LensGen®, Inc. will be featured in several activities as the European Society for Cataract and Refractive Surgery (ESCRS) event in Paris, France begins. LensGen developed Juvene™, which is the world’s first modular fluid optic IOL that uses biomimetic design principles to emulate the natural crystalline lens and provide a continuous dynamic range of vision from distance to near with high quality optics. On September 12, at the Ophthalmic Future Forums, Sumit Garg, M.D. will present an update of clinical data

LensGen® Will Present Early Results Of International “Grail” Study At ASCRS

Eric Donnenfeld M.D. Chosen for Prestigious Innovators Lecture News provided by LensGen, Inc. Apr 30, 2019, 09:15 ET IRVINE, Calif., April 30, 2019 /PRNewswire/ — LensGen®, Inc., a private California-based company focused on bringing to market Juvene™, a potentially game changing presbyopia-correcting intraocular lens (IOL) for the treatment of cataracts and presbyopia, will share results from its “Grail” Study at the ASCRS annual meeting in San Diego May 3-7. The results will include the latest available data on patients who have been treated at two international sites.   Juvene is the world’s first modular fluid optic IOL that uses biomimetic

LensGen® adds internationally recognized researcher and expert in anterior segment surgery, Sumit Garg, M.D., to its Scientific Advisory Board

Dr. Sumit (Sam) Garg is Vice Chair of Clinical Ophthalmology, Medical Director, and an Associate Professor in Cataract, Refractive, External Disease and Corneal Surgery at the Gavin Herbert Eye Institute at the University of California, Irvine. Dr. Garg is a highly-skilled clinician, surgeon, and teacher, and has expertise in cataract surgery and complication management, corneal (PKP, FLEK, DSEK, DMEK), conjunctival, and refractive surgery. Dr. Garg participates in numerous research projects, many of which he has presented at national and international meetings. In addition to his research activities, Dr. Garg has authored numerous peer-reviewed papers and book chapters. Dr. Garg currently

LensGen® Announces Funding and Patent Success

IRVINE, Calif., July 17, 2018 /PRNewswire/ — LensGen®, Inc., a private California company developing the world’s first modular, fluid-optic, curvature changing intraocular lens (IOL) is reporting significant progress in its effort to transform how presbyopia is addressed. The Company successfully achieved a key clinical performance milestone which triggered the release of $11 million in funding as part of the Series A Financing that was announced in May 2017. Also, lead investor HOYA Group opted to invest an additional $4.4M that was an available option in the Series A financing. “We are pleased that LensGen is continuing to make outstanding progress